Researchers may have discovered how Ebola invades our immune system and disrupts the host immune response.
Health authorities in the Democratic Republic of Congo plan to introduce a second experimental Ebola vaccine, manufactured by Johnson & Johnson, from mid-October.
The results of a new study suggest that – compared with the general population – Ebola survivors may be at a significantly increased risk of death, particularly during the first year following hospital discharge.
A study of four Ebola therapeutics demonstrated that two drugs showed significantly improved survival rates, leading to the trial being halted early.
The outbreak of Ebola in the Democratic Republic of Congo has seen over 2612 cases and 1756 mortalities since it was first announced by the WHO on 1 August 2018. One year on we ask, what have the major milestones been of this outbreak? And where are we now; is there an end in sight?
The fourth International Health Regulations Emergency Committee meeting has concluded by declaring a Public Health Emergency of International Concern, following the recent Ebola virus disease outbreak in the Democratic Republic of the Congo.
The Ministry of Health and WHO have reported the first case of Ebola confirmed in Uganda during the outbreak in neighbouring Democratic Republic of the Congo.
ECCMID19: Immune response to Ebola 2 years post-infection could provide clues for vaccine development
Two years after Ebola infection, survivors exhibit specific memory T cell responses against ebolavirus, according to new research presented at ECCMID.
A recently discovered species of the ebolavirus, the Bombali virus, has been identified in bats in Kenya, marking the first time any ebolavirus has been found in wildlife on the east coast of Africa.
A new population-based survey has reported that low levels of public trust could have impacted the Ebola control efforts in the Democratic Republic of Congo, with a quarter of individuals not believing the virus was real and refusing vaccination.